Investor Service Announcement no. 4/2007
To OMX Nordic Exchange Hørsholm, Denmark, August 27 2007
LifeCycle Pharma Appoints Francesca DeMartino as Director, Investor Relations
and Corporate Communications
Summary: LifeCycle Pharma strengthens financial communications with the
appointment of Francesca DeMartino to Director, Investor Relations and Corporate
Communications.
Hørsholm, Denmark, August 27, 2007; LifeCycle Pharma A/S (OMX:LCP), an emerging
specialty pharmaceutical company focused on developing and commercializing
differentiated versions of existing drugs in large therapeutic areas such as
cardiovascular disease, organ transplantation and immunosuppression, including
recently Food and Drug Administration (“FDA”) approved LCP-FenoChol, a
fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, today
announced that Francesca DeMartino has been named Director, Investor Relations
and Corporate Communications, effective September 4, 2007.
Ms. DeMartino will be based in the U.S. and will be responsible for developing,
implementing and leading LCP´s investor relations and corporate communications
strategic initiatives, including proactive communication with equity research
analysts, shareholders, media, and other financial constituencies in order to
raise the visibility of the Company among the investment community.
“Francesca's appointment emphasizes our commitment to providing high quality
financial communications,” said Dr. Flemming Ornskov, President and CEO of LCP.
“Francesca's healthcare industry knowledge, analytical capabilities, and
familiarity with U.S. investors and markets will be vital to our success as we
continue to advance our product pipeline from clinical development to
commercialization.”
Ms. DeMartino's experience spans positions across corporate finance and
corporate communications, primarily in the healthcare industry. Prior to joining
LCP, Ms. DeMartino most recently held the position of Director, Investor
Relations at OMRIX Biopharmaceuticals, Inc. (NASDAQ: OMRI). During OMRIX' first
year as a publicly-traded company, she developed and implemented the investor
relations program and helped increase visibility and shareholder value. Prior to
OMRIX, Ms. DeMartino spent numerous years at leading investor relations and
public relations agencies such as GCI Group, a WPP company, and The Ruth Group,
both in New York City. Ms. DeMartino began her career at Deutsche Banc Alex.
Brown (now Deutsche Bank Securities Inc.) where, as a member of the Health Care
Investment Banking Group, she structured comprehensive financial and strategic
analyses for a broad range of transactions and advised public and private
companies in all sectors of the healthcare industry.
Ms. DeMartino holds a B.A. in International and Area Studies from the University
of California, Berkeley and a minor in Business Administration from the Walter
A. Haas School of Business.
For further information please contact:
LifeCycle Pharma A/S
Michael Wolff Jensen
Executive Vice President and CFO
Tel. +45 70 33 33 00
Mob. +45 40 74 62 44
Email. mwj@lcpharma.com
Francesca DeMartino
Director, Investor Relations & Corporate Communications
Tel. +1 201 633 4729
Email. fdm@lcpharma.com
---oo0oo---
About LifeCycle Pharma A/S ("LCP A/S")
LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty
pharmaceutical company focused on developing and commercializing a portfolio of
innovative products in therapeutic areas such as cholesterol management,
hypertension, organ transplantation and autoimmune diseases. LCP's proprietary
MeltDose® technology, offers lower dosing, reduced side effects, improved safety
and patient compliance, and reduced product development costs and times.
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and
hypertriglyceridemia, is LCP's first FDA approved product (approved on August
10, 2007). LCP is listed on the OMX Nordic Exchange under the trading symbol
(OMX:LCP). For further information, please visit www.lcpharma.com.
LifeCycle Pharma Appoints Francesca DeMartino as Director, Investor Relations and Corporate Communications
| Source: Veloxis Pharmaceuticals A/S
Attachments
